Systemic autoimmune rheumatic diseases as paraneoplastic phenomena: 3 illustrative case reports and narrative review of the literature

References

• Goldblatt F, O’neill SG. Clinical aspects of autoimmune rheumatic diseases. Lancet. 2013;382(9894):797–808.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Daikh DI, Betteridge N, et al. Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the EULAR and ACR. Ann Rheum Dis. 2018;77:829–832.
   PubMed Web of Science ®Google Scholar
• Ingegnoli F, Ughi N, Mihai C. Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis. Best Pract Res Clin Rheumatol. 2018;32(2):223–240.
   PubMed Web of Science ®Google Scholar
• Svensson J, Arkema EV, Lundberg IE, et al. Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based study. Rheumatology. 2017;56(5):802–810. DOI:10.1093/rheumatology/kew503
   PubMed Web of Science ®Google Scholar
• Manger B, Schett G. Palmar fasciitis and polyarthritis syndrome—systematic literature review of 100 cases. Semin Arthritis Rheum. 2014;44(1):105–111.
   PubMed Web of Science ®Google Scholar
• Manger B, Schett G. Paraneoplastic syndromes in rheumatology. Nat Rev Rheumatol. 2014;10(11):662–670.
   PubMed Web of Science ®Google Scholar
• Geng G, Yu X, Jiang J, et al. Aetiology and pathogenesis of paraneoplastic autoimmune disorders. Autoimmun Rev. 2020;19(1):102422. DOI:10.1016/j.autrev.2019.102422
   PubMed Web of Science ®Google Scholar
• Shah AA, Casciola‐rosen L, Rosen A. Review: cancer‐induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol. 2015;67(2):317–326.
   PubMed Web of Science ®Google Scholar
• Lazzaroni MG, Cavazzana I, Colombo E, et al. Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening. J Rheumatol. 2017;44(5):639–647. DOI:10.3899/jrheum.160817
   PubMed Web of Science ®Google Scholar
• Lepri G, Catalano M, Bellando-Randone S, et al. Systemic sclerosis association with malignancy. Clin Rev Allergy Immunol. 2022;63(3):398–416. DOI:10.1007/s12016-022-08930-4
   PubMed Web of Science ®Google Scholar
• Cappelli LC, Shah AA. The relationships between cancer and autoimmune rheumatic diseases. Best Pract Res Clin Rheumatol. 2020;34(1):101472.
   PubMed Web of Science ®Google Scholar
• Castillo R, Albayda J. Dermatomyositis: autoantibodies and their corresponding phenotypes. Curr Treatm Opt Rheumatol. 2017;3(4):254–266.
   Google Scholar
• Stochmal A, Czuwara J, Trojanowska M, et al. Antinuclear antibodies in systemic sclerosis: an update. Clin Rev Allergy Immunol. 2019;58(1):40–51. DOI:10.1007/s12016-018-8718-8
   Web of Science ®Google Scholar
• Damoiseaux J, Andrade LEC, Carballo OG, et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA Patterns (ICAP) perspective. Ann Rheum Dis. 2019;78(7):879–889. DOI:10.1136/annrheumdis-2018-214436
   PubMed Web of Science ®Google Scholar
• van den Hoogen F, Khanna D, Fransen J, et al. Classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737–2747. DOI:10.1002/art.38098
   PubMed Web of Science ®Google Scholar
• Parker JC, Burlingame RW, Webb TT, et al. Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA. Rheumatology. 2008;47(7):976–979. DOI:10.1093/rheumatology/ken201
   PubMed Web of Science ®Google Scholar
• Scleroderma [Internet]. Lab Tests Online. 2020. Available from: https://labtestsonline.org/conditions/scleroderma.
   Google Scholar
• Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Sci (NY). 2014;343(6167):152–157. DOI:10.1126/science.1246886
   PubMed Web of Science ®Google Scholar
• Shah AA, Casciola-Rosen L. Cancer and Scleroderma: a paraneoplastic disease with implications for malignancy screening. Curr Opin Rheumatol. 2015;27(6):563.
   PubMed Web of Science ®Google Scholar
• Miller ML, Amato AA, Vleugels RA Overview of and approach to the idiopathic inflammatory myopathies [internet]. Up To Date. 2021. Available from: https://www.uptodate.com/contents/overview-of-and-approach-to-the-idiopathic-inflammatory-myopathies/print.
   Google Scholar
• Madan V, Chinoy H, Griffiths CEM, et al. Defining cancer risk in dermatomyositis. Part I. Clin Exp Dermatol. 2009;34(4):451–455. DOI:10.1111/j.1365-2230.2009.03216.x
   PubMed Web of Science ®Google Scholar
• Dourmishev LA, Dourmishev AL, Schwartz RA. Dermatomyositis: cutaneous manifestations of its variants. Int J Dermatol. 2002;41(10):625–630.
   PubMed Web of Science ®Google Scholar
• Madan V, Chinoy H, Griffiths CEM, et al. Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology. Clin Exp Dermatol. 2009;34(5):561–565. DOI:10.1111/j.1365-2230.2009.03227.x
   PubMed Web of Science ®Google Scholar
• de Vooght J, Vulsteke JB, de Haes P, et al. Anti-TIF1-γ autoantibodies: warning lights of a tumour autoantigen. Rheumatol (United Kingdom). Oxford University Press. 2020;59(3):469–477.
   PubMed Web of Science ®Google Scholar
• van Horebeek N, Vulsteke J-B, Bossuyt X, et al. Detection of multiple myositis-specific autoantibodies in unique patients with idiopathic inflammatory myopathy: a single centre-experience and literature review: systematic review. Semin Arthritis Rheum. 2021;51(2):486–494. DOI:10.1016/j.semarthrit.2021.03.012
   PubMedGoogle Scholar
• Yang H, Peng Q, Yin L, et al. Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res Ther. 2017;19(1):1–9. DOI:10.1186/s13075-017-1469-8
   PubMedGoogle Scholar
• Jakubaszek M, Kwiatkowska B, Maślińska M. Polymyositis and dermatomyositis as a risk of developing cancer. Reumatologia/Rheumatology. 2015;53(2):101–105.
   Google Scholar
• András C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol. 2008;35(3):438–444.
   PubMed Web of Science ®Google Scholar
• Kardes S, Gupta L, Aggarwal R. Cancer and myositis: who, when, and how to screen. Best Pract Res Clin Rheumatol. 2022;36(2):101771.
   PubMed Web of Science ®Google Scholar
• Amoura Z, Duhaut P, Huong DLT, et al. Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. Cancer Epidemiol, Biomarkers Prev. 2005;14(5):1279–1282. DOI:10.1158/1055-9965.EPI-04-0624
   PubMed Web of Science ®Google Scholar
• Chandiramani M, Joynson C, Panchal R, et al. Dermatomyositis as a paraneoplastic syndrome in carcinosarcoma of uterine origin. Clin Oncol. 2006;18(9):641–648. DOI:10.1016/j.clon.2006.07.008
   Web of Science ®Google Scholar
• Bolibar EP, Raya JS, Simeon CP, et al. Palmar fasciitis and polyarthritis as a paraneoplastic syndrome associated with ovarian carcinoma: a case report. BMJ Case Rep. 2009;2009(dec21 1):bcr0520091899. DOI:10.1136/bcr.05.2009.1899
   Google Scholar
• Vulsteke JB, Smith V, Bonroy C, et al. Identification of new telomere- and telomerase-associated autoantigens in systemic sclerosis. J Autoimmun. 2023;135:102988.
   PubMed Web of Science ®Google Scholar
• Kajikawa H, Sobajima T, Koiwai C, et al. Palmar fasciitis with polyarthritis-associated ovarian cancer: case report and literature review. Mol Clin Oncol. 2018;8:292–295.
   PubMed Web of Science ®Google Scholar
• Shah AA, Cappelli L, Schur PH, et al. Malignancy and rheumatic disorders [internet]. Up To Date. 2021. Available from: https://www-uptodate-com.kuleuven.e-bronnen.be/contents/malignancy-and-rheumatic-disorders/print?search=palmarfasciitis&source=search_result&selectedTitle=1~3&usage_type=default&display_rank=1.
   Google Scholar
• Richter MD, Crowson C, Kottschade LA, et al. Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients. Arthritis Rheumatology. 2019;71(3):468–475. DOI:10.1002/art.40745
   PubMed Web of Science ®Google Scholar
• Estenaga A, Rodriguez-Garijo N, Tomás-Velázquez A, et al. Immunotherapy-intensified paraneoplastic dermatomyositis. Indian J Dermatol Venereol Leprol. 2022;88:93–96.
   Web of Science ®Google Scholar
• Kostine M, Truchetet ME, Schaeverbeke T. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy. Rheumatology. 2019;58(Supplement_7):68–74.
   Google Scholar
• Cappelli LC, Bingham CO. Spectrum and impact of checkpoint inhibitor-induced irAes. Nat Rev Rheumatol. 2020;17(2):69–70.
   Web of Science ®Google Scholar